In addition, we studied its role as a possible antigenic target in SUM149, a cellular model for basal-type IBC and its isogenic derived cell line-rSUM149 cells [31] with acquired therapeutic resistance to lapatinib, an epidermal growth receptor (EGFR/HER2) dual kinase inhibitor approved for use in IBC patients. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.